Peptide detail

Tirzepatide

Tirzepatide (Mounjaro) represents a breakthrough in weight loss and diabetes management as the first dual GIP/GLP-1 receptor agonist. By simultaneously targeting both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, it achieves superior efficacy compared to single-receptor agonists. Clinical trials have demonstrated average weight loss of 15-20% of body weight at the highest dose, with significant improvements in blood sugar control, blood pressure, and cholesterol levels. The medication works through multiple mechanisms: reducing appetite and food intake, slowing gastric emptying, improving insulin sensitivity, and promoting satiety. It has shown particular effectiveness in individuals with type 2 diabetes, where it not only helps with weight loss but also significantly improves glycemic control and reduces the risk of cardiovascular complications.